KYMR insider trading
NasdaqGM HealthcareKymera Therapeutics, Inc.: insider trade history from SEC Form 4 filings.
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Company website: www.kymeratx.com
KYMR insider activity at a glance
FilingIQ tracks 754 insider transactions for KYMR in filings since Aug 25, 2020. The most recent transaction is dated Oct 1, 2026.
Across the full history, 45 open-market purchases
and 530 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on KYMR insider trades is 54.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest KYMR Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding KYMR
Frequently asked
- How many insider trades does FilingIQ track for KYMR?
- FilingIQ tracks 754 Form 4 insider transactions for KYMR (Kymera Therapeutics, Inc.), covering filings from Aug 25, 2020 onwards. 11 of those are dated within the last 90 days.
- Are KYMR insiders net buyers or net sellers?
- Across the full Form 4 history for KYMR, 45 transactions (6%) were open-market purchases and 530 (70%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does KYMR insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is KYMR in?
- Kymera Therapeutics, Inc. (KYMR) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $6.99B.
Methodology & sources
Every KYMR insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.